


# Patient Card

For patients receiving treatment with nivolumab, or nivolumab in combination with ipilimumab or another therapy

This document has been approved by HSA as of 17-09-2025.  
Local Approval Number: 1506-SG-2500011










## IMPORTANT Information for Patients

Carry this card with you at all times to inform healthcare professionals that you are receiving treatment with nivolumab, or nivolumab in combination with ipilimumab or another therapy.

- 
- Nivolumab is a medicine that helps reactivate your immune system’s T-cells (a type of white blood cells) so they regain the ability to fight cancer cells.
- 
- With nivolumab, there is a risk that your activated immune system can harm healthy cells in your body, which may cause potentially serious or even life-threatening side effects. These side effects may affect different parts of the body.
- 
- Some signs and/or symptoms that occur in one part of your body may be related to a side effect in another part of your body (for example, a yellowing skin may represent a liver problem).
- 
- If you have any signs or symptoms, tell your doctor right away.** This includes any other possible side effects not included in this card.

## SIGNS AND SYMPTOMS TO LOOK OUT FOR

Parts of your body	Possible signs and symptoms
 Chest (heart and lungs)	Breathing difficulties, cough (new or worsening), wheezing, chest pain, irregular heartbeat, palpitations (increased awareness of your heartbeat compared to normal)
 Gut (stomach and bowels)	Diarrhoea (watery, loose or soft stools), blood or mucus in stools, dark-coloured, tarry and sticky stools, pain or tenderness in your stomach or abdominal area, heartburn or indigestion
 Liver	Jaundice (eye or skin yellowing), pain on the right side of your stomach area
 Kidneys	Change in amount and/or frequency of urine, urine of a darker colour than normal (tea-coloured)
 Hormone-producing glands (including diabetes)	Headaches, blurry or double vision, fatigue (tiredness), weight changes, behavioural changes (e.g., lower sex drive, irritability or forgetfulness), excessive thirst, increased appetite with weight loss, weakness, drowsiness, depression, feeling unwell, change in amount and/or frequency of urine
 Skin	Rash, itch, blisters and/or peeling of the skin, ulcers, dry skin, skin nodules
 Other	Weakness, fatigue (tiredness), increased or decreased appetite, nausea, vomiting, tingling or numbness in arms and legs, difficulty walking, fever, swollen lymph nodes, headache, seizures (fits), stiff neck, confusion, hallucinations, drowsiness, muscle or joint pains, stiffness, dark urine, eye pain or redness, blurry vision, or other vision problems, feeling unwell, ulcers in the mouth or other mucous membranes (e.g., nose, eyelids)

IMPORTANT

- Early assessment and management of side effects by your doctor reduces the likelihood that treatment with nivolumab, or nivolumab in combination with ipilimumab or another therapy will need to be temporarily or permanently stopped.
- Signs and symptoms that may appear mild can quickly worsen if left untreated.
- **DO NOT** try to treat these symptoms yourself.
- Signs and symptoms can appear during treatment or may be delayed and may occur weeks to months after your last injection.

For more information, please talk to your doctor.

IMPORTANT Information for Healthcare Professionals

- This patient is treated with nivolumab, or nivolumab in combination with ipilimumab or another therapy, which may increase the risk of immune-related adverse reactions.
- Immune-related adverse reactions may appear at any time during treatment or months after its discontinuation.
- Assess patients for signs and symptoms of immune-related adverse reactions including, but not limited to, those listed on this card. Early diagnosis and appropriate management are essential to minimise life-threatening complications.
- Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific immune-related adverse reactions.
- Please refer to the OPDIVO (nivolumab) Singapore package insert or call Medical Information on 1800 415 5182 for more information.

The healthcare professional treating this patient with nivolumab, or nivolumab in combination with ipilimumab or another therapy should complete the 'My Doctor's Contact Information' section of this Patient Card.

My Doctor's Contact Information

(who prescribed nivolumab, or nivolumab in combination with ipilimumab or another therapy)

Name of Doctor: \_\_\_\_\_

Office Phone: \_\_\_\_\_

After-Hours Phone: \_\_\_\_\_

My Contact Information

My Name: \_\_\_\_\_

My Phone Number: \_\_\_\_\_

Emergency Contact (name and phone number):  
\_\_\_\_\_